Vir Biotechnology Inc (VIR) Is A Buy According To Analysts

Vir Biotechnology Inc (NASDAQ:VIR) has a beta value of 0.50 and has seen 0.48 million shares traded in the recent trading session. The company, currently valued at $1.46B, closed the recent trade at $10.71 per share which meant it gained $0.09 on the day or 0.78% during that session. The VIR stock price is -156.58% off its 52-week high price of $27.48 and 28.94% above the 52-week low of $7.61. The 3-month trading volume is 987.37K shares.

Vir Biotechnology Inc (NASDAQ:VIR) trade information

Sporting 0.78% in the green today, the stock has traded in the red over the last five days, when the VIR stock price touched $10.71 or saw a rise of 16.91%. Year-to-date, Vir Biotechnology Inc shares have moved 6.44%, while the 5-day performance has seen it change -15.42%. Over the past 30 days, the shares of Vir Biotechnology Inc (NASDAQ:VIR) have changed 9.60%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Vir Biotechnology Inc (VIR) estimates and forecasts

Figures show that Vir Biotechnology Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 13.07% over the past 6 months, with this year growth rate of 22.22%, compared to 15.40% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -34.12% over the past 5 years. Earnings growth for 2024 is a modest 24.16% while over the next 5 years, the company’s earnings are expected to increase by 7.00%.

VIR Dividends

Vir Biotechnology Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.